Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

22.96B

Market cap22.96B

Price-Earnings ratio

14.75

Price-Earnings ratio14.75

Dividend yield

—

Dividend yield—

Average volume

1.79M

Average volume1.79M

High today

—

High today—

Low today

—

Low today—

Open price

$115.89

Open price$115.89

Volume

0.00

Volume0.00

52 Week high

$132.60

52 Week high$132.60

52 Week low

$84.02

52 Week low$84.02

Stock Snapshot

With a market cap of 22.96B, Incyte(INCY) trades at $113.31. The stock has a price-to-earnings ratio of 14.75.

On 2026-10-27, Incyte(INCY) shares started trading at $115.89, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.79M.

The stock's 52-week range extends from a low of $84.02 to a high of $132.60.

INCY News

Simply Wall St 1d

KRAS Cancer Trial Partnership Might Change The Case For Investing In Incyte

Genmab and Incyte recently announced a clinical trial collaboration to test petosemtamab with Incyte’s KRAS G12D inhibitor INCB161734 plus standard chemotherapy...

Simply Wall St 3d

Incyte Enters KRAS G12D Colon Cancer Trial Collaboration With New Combo Focus

Incyte (NasdaqGS: INCY) and Genmab agreed a new clinical trial collaboration to study treatments for KRAS G12D-mutated metastatic colorectal cancer. The partne...

Zacks 4d

Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?

Incyte Corporation (INCY Quick QuoteINCY - Free Report) is scheduled to report third-quarter 2026 earnings on Oct. 29, before the opening bell. The Zacks...

Analyst ratings

52%

of 31 ratings

Buy

41.9%

Hold

51.6%

Sell

6.5%

More INCY News

Simply Wall St 5d

Incyte Could Be 12% Below Fair Value On ESMO Oncology Data Focus

Incyte (INCY) is drawing attention after announcing plans to showcase new oncology data at the European Society of Medical Oncology Congress 2026 in Madrid, sta...

TipRanks 6d

Incyte price target raised to $140 from $138 at TD Cowen

TD Cowen raised the firm’s price target on Incyte (INCY) to $140 from $138 and keeps a Buy rating on the shares. The firm decreased their 2026 estimatse to acco...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.